Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016
Published Jul 30, 2016
63 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016, provides in depth analysis on Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
- The report reviews Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demogr

  
Source:
Document ID
GMDHC0439TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview71
Therapeutics Development83
  Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Stage of Development81
  Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Therapy Area91
  Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Indication101
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Products under Development by Companies132
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Therapeutics Assessment157
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action162
  Assessment by Route of Administration182
  Assessment by Molecule Type202
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Companies Involved in Therapeutics Development229
  Bayer AG221
  Bharat Biotech International Limited231
  F. Hoffmann-La Roche Ltd.241
  Grifols, S.A.251
  Hyundai Pharmaceutical Co., Ltd.261
  Kedrion S.p.A.271
  Nostrum Pharmaceuticals, LLC281
  Omeros Corporation291
  ProMetic Life Sciences Inc.301
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Drug Profiles3116
  alteplase Drug Profile312
  OMS-616 Drug Profile331
  plasminogen (human) Drug Profile341
  plasminogen (human) Drug Profile352
  plasminogen (recombinant) Drug Profile371
  Recombinant Prourokinase Drug Profile381
  Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder Drug Profile391
  SMRX-11 Drug Profile401
  TAL-0500018 Drug Profile412
  THR-100 Drug Profile431
  TMS-007 Drug Profile441
  tranexamic acid Drug Profile451
  TTS-01 Drug Profile461
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Dormant Projects472
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Discontinued Products491
Plasminogen (Plasmin or PLG or EC 3.4.21.7) Featured News &Press Releases5012
  Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA501
  May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA501
  May 10, 2016: Major new global study identifies a safer treatment of acute stroke511
  May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA521
  Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke532
  Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case551
  Nov 04, 2015: Prometic S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition561
  Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients561
  Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug571
  Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke581
  Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA581
  Aug 22, 2014: MHRA To Review Ischemic Stroke Drug591
  Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials592
  Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis611
  Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin611
Appendix622
  Methodology621
  Coverage621
  Secondary Research621
  Primary Research621
  Expert Panel Validation621
  Contact Us621
  Disclaimer631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Plasminogen-Plasmin-or-PLG-or-EC-3-4-21-7-Pipeline-Review-H2-2016-2088-16336>
  
APA:
Global Markets Direct - Market Research. (2016). Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Plasminogen-Plasmin-or-PLG-or-EC-3-4-21-7-Pipeline-Review-H2-2016-2088-16336>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.